The survival curve of CD38 bimodal CLL patients overlaps that of CD38⁺ patients.

(A) Kaplan-Meier curves show cumulative survival of CD38⁻, CD38 bimodal expression, and CD38⁺ patients. CD38⁻ patients have a significantly longer survival (median survival not reached) than CD38 bimodal expression (median survival, 156 months; P < .001) and CD38⁺(median survival, 183 months; P = .001) subsets. The differences among the 3 curves are statistically significant (P = .002). (B) No significant differences were observed when the survival curves of CD38 bimodal expression patients were analyzed according to the 30% positivity cutoff (< 30% and ≥ 30%).